CD93 and neoplasm: Sun et al. (23) demonstrated that IGFBP7 acted as a ligand of CD93 and disrupted normalizes tumor vasculature, including reducing pericyte and smooth muscle cell coverage on blood vessels and increasing vascular permeability and leakage by the CD93/IGFBP7 pathway.